Vollständige Version anzeigen : Chiron
Die Biotech-Konsolidierung geht weiter, diesmal in kleinerem Rahmen: Die Aktionäre des US-Biotech-Unternehmens haben Grund zum Feiern. Chiron übernimmt den Konkurrenten Matrix Pharmaceuticals, der durch den Fehlschlag eines Krebsmedikaments verkraften muss. Entsprechend niedrig ist der Kaufpreis: Nur 61 Millionen US-Dollar blättert Chiron auf den Tisch. Chiron hat es auf Matrix-Expertise bei Krebspräparaten abgesehen. Der Matrix-Aktie wird der Deal trotzdem kurzfristig besser bekommen als dem Chiron-Papier.
© 2002 sharper.de
Chiron WKN 869640
Matrix WKN 883845
Biotech :freak:
Dawnrazor
08.01.2002, 09:38
Der Matrix-Aktie wird der Deal trotzdem kurzfristig besser bekommen als dem Chiron-Papier.
Na ja...
Schlußkurs am Freitag vor der Übernahme: 2,59 USD
Schlußkurs am Montag nach der Übernahme: 2,18 USD (-16%)
Jetzt wird sie bis zum Abschluß der Transaktion nur noch um ein paar Cents schwanken, wenn nichts Außergewöhnliches passiert.
Ein Erfolg, der ein schönes Zubrot nach sich ziehen wird. Das US-Biotech-Unternehmen Chiron erhält die US-Zulassung für ein Testgerät. Die Gesundheitswächter gaben dem Bluttestsystem Procleix grünes Licht. Jetzt hat das Gerät die offizielle Genehmigung, Blutkonserven nach HIV- und Hepatitis C-Viren zu testen. Das Witzige dabei: Procleix kam bereits seit zwei Jahren zum Einsatz. Die Zulassung ist trotzdem Gold wert, da Chiron jetzt von seinen Abnehmern den vollen Preis verlangen kann. Bis jetzt erhält Chiron nur die Kosten des Produkts erstattet. Die Nachricht wird der Aktie gut tun.
Quelle:sharper
:spin:
Chiron +5,07 18:38
Chiron und Gen-Probe geben bekannt, dass die US-Gesundheitsbehörde FDA die Tests für eine Technologie genehmigt haben, die zur Bluttransfusion bei Patienten mit dem „West Nile“ Virus verwendet werden könnte. Die Screening Technologie kann den von Mücken übertragenen Virus erkennen, hieß es.
Chiron hat James Sulat als Finanzvorstand verloren. Sulat wird professionellen Tätigkeiten außerhalb des Pharmasektors nachgehen, hieß es. Das kalifornische Unternehmen gibt bekannt, dass David Smith, der Vice President of Finance, die Position des Finanzvorstandes auf Interimbasis begleiten wird.
Chiron Corporation gibt bekannt, die exklusiven weltweiten Entwicklungsrechte für ein Mittel von dem Schweizer Pharmakonzern Novartis AG gekauft zu haben, dass zur Behandlung von Abwehrreaktionen des Körpers nach einer Lungentransplantation eingesetzt wird. Finanzielle Details wurden einbehalten.
http://bigcharts.marketwatch.com/charts/big.chart?symb=chir&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&size=2&state=8&sid=1201&style=320&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=8332&mocktick=1
LONDON, Oct 05, 2004 (AP Online via COMTEX) -- The maker of half the United States' flu vaccine said it would supply none this year after British health officials pulled its license Tuesday.
The news means the United States will face "a significant shortage" just as the flu season begin, said Dr. Anthony Fauci, the National Institutes of Health's infectious disease chief.
Other countries will likely face similar problems.
"The implications may be significant," said Dr. Klaus Stohr, influenza chief the World Health Organization.
British authorities suspended the license of Chiron Corp. for three months because of problems at its vaccine manufacturing plant in Liverpool, England. The action means the company can't supply any flu vaccines to any market during that time, and Chiron said it would provide none during this year.
U.S. health officials were caught off-guard, learning of the developments only during a midmorning phone call. "We need to regroup," Fauci said shortly afterward.
Chiron had planned to ship 46 million to 48 million doses, but that already had been delayed by a contamination problem discovered in August in the English factory where the vaccine is made. At the time, the company said only 4 million doses were tainted but that the entire supply would be held up and re-tested.
About 1 million doses already had arrived in the United States, but it remains under Chiron's control and has not been released for use.
Flu shot campaigns usually start in October, a month before the flu season typically begins in the United States. In an average year, flu kills 36,000 people and hospitalizes another 114,000, mostly the elderly.
Less than two weeks ago, top U.S. health officials assured the public that close FDA monitoring of the rest of Chiron's supply suggested it was fine and that there would be plenty of supplies.
Dr. Walt Orenstein, formerly the top flu expert at the U.S. Centers for Disease Control and Prevention and now the associate director of the Emory Vaccine Center, said the government may have to ration available vaccine.
"It's a very serious concern. We're already in October, which is vaccine season. If we have to ration at this stage, it becomes more complicated."
If problems prevent the Chiron vaccine from being used at all this year, it's unlikely that other manufacturers could fill the gap. Aventis Pasteur, which expects to supply 52 million doses, said earlier that federal officials had asked it to make additional vaccine but that it already was at capacity and couldn't produce more until after November when existing orders are filled.
A third manufacturer, MedImmune, which makes FluMist, a new nasal spray flu vaccine for use in healthy 5- to 49-year-olds, said it couldn't produce more than the 1.5 million doses it had planned to make for this year's flu season.
That vaccine is made from modified live virus and isn't considered safe for the elderly or people with medical problems.
Worldwide, Chiron is the second leading flu vaccine manufacturer, behind French pharmaceutical company Aventis, which makes about 45 percent or 50 percent of the world's supply, Stohr said.
Chiron, based in California, makes four influenza vaccines, including Fluvirin, the top flu vaccine in Northern Europe and the No. 2 vaccine in the United States
The timing of the license suspension is particularly worrying because vaccine production goes in cycles. The manufacturing cycle for the Northern Hemisphere vaccine finished in August and manufacturers are now gearing up to make the shots for the Southern Hemisphere.
Vaccine makers do not have a lot of spare stock because they produce on demand.